Reply to "Expansion of pan-cancer mismatch repair testing: Implications for pembrolizumab eligibility and Lynch syndrome screening"
Cancer
.
2024 Oct 29.
doi: 10.1002/cncr.35625.
Online ahead of print.
Authors
Teresa S Chai
1
,
Linda H Rodgers-Fouche
1
,
Anthony R Mattia
2
,
Daniel C Chung
1
3
Affiliations
1
Center for Cancer Risk Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA.
2
Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
3
Department of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.
PMID:
39470458
DOI:
10.1002/cncr.35625
No abstract available
Publication types
Letter